scholarly journals The Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients

2021 ◽  
Vol 10 (22) ◽  
pp. 5228
Author(s):  
Hiromitsu Onoe ◽  
Kazuyuki Hirooka ◽  
Mikio Nagayama ◽  
Atsushi Hirota ◽  
Hideki Mochizuki ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Treatment Satisfaction ◽  
Fixed Combination ◽  
Conjunctival Hyperemia ◽  
Evaluation Period ◽  
Satisfaction Questionnaire ◽  
Global Satisfaction ◽  
Time Points ◽  
Superficial Punctate Keratopathy ◽  
Ophthalmic Suspension

We evaluated glaucoma patients for the efficacy, safety and satisfaction associated with switching from brinzolamide 1% and brimonidine 0.1% to a fixed combination of brinzolamide 1% and brimonidine 0.1%. A total of 22 glaucoma patients were enrolled and completed this prospective, nonrandomized study that evaluated patients who underwent treatment with at least brinzolamide 1% and brimonidine 0.1%. Patients on brinzolamide 1% and brimonidine 0.1% were switched to a brinzolamide/brimonidine fixed-combination ophthalmic suspension (BBFC). Evaluations of intraocular pressure (IOP), superficial punctate keratopathy (SPK) and conjunctival hyperemia were conducted at baseline and at 4 and 12 weeks. The Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9) was utilized to assess the change in treatment satisfaction. At baseline and at 4 and 12 weeks, the IOP was 15.0 ± 4.1, 14.8 ± 4.1 and 14.8 ± 4.1 mmHg, respectively. There were no significant differences observed at any of the time points. However, the SPK score significantly decreased at 12 weeks, even though no significant differences were observed for the conjunctival hyperemia incidence at any of the time points. After switching from brinzolamide 1% and brimonidine 0.1% to BBFC, there was a significant increase in the TSQM-9 score for convenience and global satisfaction. Both an improvement in the degree of SPK and an increase in treatment satisfaction occurred after switching from brinzolamide 1% and brimonidine 0.1% to BBFC, even though there were sustained IOP values throughout the 12-week evaluation period.

Efficacy and Tolerability of Prostaglandin-Timolol Fixed Combinations: A Meta-Analysis of Randomized Clinical Trials

2011 ◽  
Vol 22 (1) ◽  
pp. 5-18 ◽  
Author(s):  
Florent Aptel ◽  
Michel Cucherat ◽  
Philippe Denis
Keyword(s):  
Clinical Trials ◽  
Intraocular Pressure ◽  
Relative Risk ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Conjunctival Hyperemia ◽  
Time Points ◽  
Curve Change ◽  
The Mean ◽  
The Individual

Purpose To evaluate the intraocular pressure (IOP)-lowering effects and tolerability of the 3 prostaglandin-timolol fixed combinations (PG-timolol FCs). Methods Clinical trials comparing directly the PG-timolol FCs or comparing the PG-timolol FCs to their individual components were thoroughly searched. The main outcome measures were efficacy assessed by IOP (taken at 9 AM, noon, 4 PM, and over the mean diurnal curve) change at 3 months (or after 1 to 6 months of treatment if no data were available at month 3) from baseline and tolerability assessed by the incidence of conjunctival hyperemia. Results Twenty trials were identified (n=4684 patients). Intraocular pressure reduction was usually greater with the 3 PG-timolol FCs than the individual PG (mean difference [MD] 0.00 mmHg to 2.59 mmHg; p>0.1 to p<0.001). The incidence of hyperemia was significantly less with latanoprost- and bimatoprost-timolol FCs than with the individual PG (relative risk = 0.66 and 0.61; p=0.05 and p<0.001). From direct comparisons, IOP reduction was significantly greatest with bimatoprost-timolol FC, at 9 AM, 4 PM, and over the mean diurnal curve compared to latanoprost-timolol FC (MD = 0.90 mmHg to 1.48 mmHg; p<0.001) and at all time points compared to travoprost-timolol FC (MD = 0.66 mmHg to 0.90 mmHg; p<0.001). The incidence of hyperemia was not significantly less with latanoprost-timolol FC than with bimatoprost-timolol FC (relative risk = 1.32; p>0.1). Conclusions The 3 PG-timolol FCs provide a greater IOP reduction and lower incidence of hyperemia than the 3 PGs alone. The direct comparisons suggest a greater efficacy of the bimatoprost-timolol FC compared with latanoprost- and travoprost-timolol FCs.

scholarly journals Satisfaction with medication in coronary disease treatment: psychometrics of the Treatment Satisfaction Questionnaire for Medication

2016 ◽  
Vol 24 (0) ◽  
Author(s):  
Ana Carolina Sauer Liberato ◽  
Roberta Cunha Matheus Rodrigues ◽  
Thaís Moreira São-João ◽  
Neusa Maria Costa Alexandre ◽  
Maria Cecília Bueno Jayme Gallani
Keyword(s):  
Side Effects ◽  
Construct Validity ◽  
Treatment Satisfaction ◽  
Reliability And Validity ◽  
University Hospital ◽  
Southeastern Brazil ◽  
Floor Effect ◽  
Satisfaction Questionnaire ◽  
Global Satisfaction ◽  
Convergent Construct Validity

Abstract Objective: to psychometrically test the Brazilian version of the Treatment Satisfaction Questionnaire for Medication - TSQM (version 1.4), regarding ceiling and floor effect, practicability, acceptability, reliability and validity. Methods: participants with coronary heart disease (n=190) were recruited from an outpatient cardiology clinic at a university hospital in Southeastern Brazil and interviewed to evaluate their satisfaction with medication using the TSQM (version 1.4) and adherence using the Morisky Self-Reported Measure of Medication Adherence Scale and proportion of adherence. The Ceiling and Floor effect were analyzed considering the 15% worst and best possible TSQM scores; Practicability was assessed by time spent during TSQM interviews; Acceptability by proportion of unanswered items and participants who answered all items; Reliability through the Cronbach's alpha coefficient and Validity through the convergent construct validity between the TSQM and the adherence measures. Results: TSQM was easily applied. Ceiling effect was found in the side effects domain and floor effect in the side effects and global satisfaction domains. Evidence of reliability was close to satisfied in all domains. The convergent construct validity was partially supported. Conclusions: the Brazilian TSQM presents evidence of acceptability and practicability, although its validity was weakly supported and adequate internal consistency was observed for one domain.

Topical 15% Resorcinol Is Associated with High Treatment Satisfaction in Patients with Mild to Moderate Hidradenitis Suppurativa

Dermatology ◽  
2021 ◽  
pp. 1-4
Author(s):  
Alexandre Docampo-Simón ◽  
Iván Beltrá-Picó ◽  
María José Sánchez-Pujol ◽  
Rosa Fuster-Ruiz-de-Apodaca ◽  
Juan Selva-Otaolaurruchi ◽  
...  
Keyword(s):  
Side Effects ◽  
Treatment Satisfaction ◽  
Hidradenitis Suppurativa ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Satisfaction Questionnaire ◽  
Global Satisfaction ◽  
The Mean ◽  
High Treatment

<b><i>Background:</i></b> Topical 15% resorcinol is commonly used in clinical practice for the treatment of nodules and abscesses in patients with hidradenitis suppurativa (HS). It has been shown to be clinically effective in some small studies, but data on satisfaction perceived by patients are lacking. The Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 is a validated measure of patient satisfaction, evaluating four domains: effectiveness, side effects, convenience, and global satisfaction. Our objective was to obtain data from HS patients regarding resorcinol treatment satisfaction and its relationship with clinical and epidemiological variables. <b><i>Methods:</i></b> We performed a cross-sectional study providing TSQM version 1.4 questionnaires to HS patients who had been prescribed topical resorcinol during the previous 24 months. <b><i>Results:</i></b> Ninety-two patients answered the questionnaire. Eighty-five out of 92 (92.4%) were Hurley II and 7 Hurley I. The mean total score was 317.5 out of 400 (71.0 points in effectiveness, 93.6 in side effects, 79.3 in convenience, and 73.2 in global satisfaction). Total score was higher in men than in women (329.7 vs. 311.6, <i>p</i> = 0.026) and higher scores on convenience were seen in patients who were not overweight or obese (86.9 vs. 77.1, <i>p</i> = 0.016). Most patients (65, 70.6%) denied having any side effect. 78 (84.8%) of the patients would recommend the treatment. <b><i>Conclusion:</i></b> The results of this study suggest that HS patients treated with resorcinol 15% are very satisfied with this treatment.

scholarly journals A Masked, Randomized, Phase 3 Comparison of Triple Fixed-Combination Bimatoprost/Brimonidine/Timolol versus Fixed-Combination Brimonidine/Timolol for Lowering Intraocular Pressure

2017 ◽  
Vol 2017 ◽  
pp. 1-9 ◽  
Author(s):  
Curt Hartleben ◽  
Juan Camilo Parra ◽  
Amy Batoosingh ◽  
Paula Bernstein ◽  
Margot Goodkin
Keyword(s):  
Intraocular Pressure ◽  
Fixed Combination ◽  
Open Angle Glaucoma ◽  
Sensitivity Analyses ◽  
Conjunctival Hyperemia ◽  
Mitt Population ◽  
Ocular Side ◽  
Secondary Endpoints ◽  
Intent To Treat ◽  
Primary Variable

Objective.To evaluate the efficacy and safety of triple fixed-combination bimatoprost 0.01%/brimonidine 0.15%/timolol 0.5% (TFC) versus dual fixed-combination brimonidine 0.2%/timolol 0.5% (DFC) in primary open-angle glaucoma and ocular hypertension.Methods.Patients with intraocular pressure (IOP) ≥23 and ≤34 mmHg were randomized to twice-daily TFC or DFC. The primary variable is the change in worse eye mean IOP from baseline at week 12 (modified intent-to-treat (mITT) population). Secondary endpoints are mean IOP and mean change from baseline at weeks 1, 2, 4, 8, and 12 (mITT population). TFC superiority was demonstrated if the primary variable favored TFC (p≤0.05). Sensitivity analyses were conducted, and safety was assessed at all visits.Results.TFC (n=93) provided greater IOP reductions from baseline than DFC (n=97) at week 12 (treatment difference, 0.85 mmHg;p=0.028) and all other visits. TFC was also superior to DFC in patients with high baseline IOP (i.e., IOP ≥ 25 mmHg;p≤0.011). Conjunctival hyperemia, ocular irritation, and dry eye were reported more often with TFC (p≤0.016); however, discontinuations for ocular adverse events were similar between treatments.Conclusions.TFC demonstrated IOP-lowering benefits that outweigh the risk of predominantly mild ocular side effects, which may be particularly relevant in patients who require greater IOP lowering to prevent/delay disease progression. This trial is registered with ClinicalTrials.gov registry number:NCT01241240.

scholarly journals Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?

2016 ◽  
Vol 23 (4) ◽  
pp. 604-613 ◽  
Author(s):  
Patrick Vermersch ◽  
Jeremy Hobart ◽  
Catherine Dive-Pouletty ◽  
Sylvie Bozzi ◽  
Steven Hass ◽  
...  
Keyword(s):  
Factor Analysis ◽  
Construct Validity ◽  
Treatment Satisfaction ◽  
Internal Validity ◽  
Internal Consistency Reliability ◽  
Measurement Properties ◽  
Patient Treatment ◽  
Group Differences ◽  
Satisfaction Questionnaire ◽  
Global Satisfaction

Background: The Treatment Satisfaction Questionnaire for Medication (TSQM) was designed to assess patient treatment satisfaction in chronic diseases. Its performance has not been examined in multiple sclerosis (MS). The 14 items of the TSQM cover four domains: Effectiveness, Side Effects, Convenience, and Global Satisfaction. Objective: To evaluate performance of the TSQM in patients with relapsing MS, using data collected from the TENERE study (NCT00883337), in which 324 patients received oral teriflunomide or subcutaneous interferon beta-1a for ⩾48 weeks. Methods: Five measurement properties were examined using traditional psychometric methods: data completeness, scale-to-sample targeting, scaling assumptions, reliability (including test–retest), and construct validity (internal: item-level scaling success, confirmatory factor analysis, and exploratory factor analysis; external: convergence, discrimination, and group differences). Results: There were few (<2%) missing item data; domain scores could be computed for all patients. Score distributions were skewed toward higher satisfaction; two domains had marked ceiling effects. Scaling assumptions were supported. Internal consistency reliability was high (Cronbach’s α > 0.90). Internal validity tests supported item groupings. Correlations supported convergent and discriminant construct validity; hypothesis testing supported group differences validity. Conclusion: This investigation found the TSQM to be a useful tool, exhibiting good psychometric measurement properties in patients with relapsing MS in the TENERE study.

scholarly journals Effects of topical levobunolol or fixed combination of dorzolamide-timolol or association of dorzolamide-levobunolol on intraocular pressure, pupil size, and heart rate in healthy cats

2008 ◽  
Vol 60 (5) ◽  
pp. 1045-1052 ◽  
Author(s):  
A.P. Ribeiro ◽  
D.P. Junior ◽  
T. Champion ◽  
M.A. Brunetto ◽  
A.A. Camacho ◽  
...  
Keyword(s):  
Heart Rate ◽  
Intraocular Pressure ◽  
Synergistic Effect ◽  
Pupil Size ◽  
Fixed Combination ◽  
Conjunctival Hyperemia ◽  
Baseline Values

The effects of topical levobunolol with the fixed combination of 2% dorzolamide-0.5% timolol and the association of 2% dorzolamide with 0.5% levobunolol on intraocular pressure (IOP), pupil size (PS), heart rate (HR), and conjunctival hyperemia in eighteen halthy cats were investigated and compared. IOP, PS, HR, and conjuntival hyperemia were daily recorded at three times (9a.m., 2p.m., and 6p.m.). Three groups were formed (n=6), and one eye of each animal was randomly selected and treated with topical levobunolol (L), or commercial combination of dorzolamide-timolol (DT), or the association of dorzolamide with levobunolol (DL). The first day (0) consisted of recording of baseline values. On the next four consecutive days, drugs were instilled at 8a.m. and 8p.m. and measurements were taken at the same times fore cited. Comparing with the baseline values, all evaluated parameters significantly decreased (P<0.001). Conjuntival hyperemia was not seen. Levobunolol significantly declined IOP, PS, and HR in normal cats, and showed a stronger effect in lowering HR, when compared to dorzolamide-timolol effect. No synergistic effect in IOP declining was noted when levobunolol dorzolamide was added to levobunolol.

scholarly journals Linguistic Validation of the Endometriosis Treatment Satisfaction Questionnaire (ETSQ) in 3 Languages for Endometriosis Patients

2018 ◽  
Vol 21 ◽  
pp. S226-S227
Author(s):  
B Brandt ◽  
AM Soliman ◽  
T Poepsel ◽  
ES Yohe Moore ◽  
E McCullough ◽  
...  
Keyword(s):  
Treatment Satisfaction ◽  
Linguistic Validation ◽  
Satisfaction Questionnaire

Prophylactic effect of brinzolamide–brimonidine fixed combination on intraocular pressure spikes after intravitreal anti-VEGF injections

2021 ◽  
Author(s):  
Maria Dettoraki ◽  
Eleni Rapti ◽  
Dimitrios Fragkos ◽  
Ioannis Theiopoulos ◽  
Anthi Legaki ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Fixed Combination ◽  
Prophylactic Effect ◽  
Anti Vegf

Ophthalmologist Attitudes regarding Fixed Combination Treatment for Glaucoma in the European Union

2009 ◽  
Vol 19 (4) ◽  
pp. 588-593 ◽  
Author(s):  
William C. Stewart ◽  
Bonnie Kruft ◽  
Lindsay A. Nelson ◽  
Jeanette A. Stewart
Keyword(s):  
Quality Of Life ◽  
European Union ◽  
Intraocular Pressure ◽  
Electronic Mail ◽  
Fixed Combination ◽  
The European Union ◽  
Perceived Safety ◽  
Popular Method ◽  
First Choice

Purpose To survey ophthalmologists in the European Union to determine their fixed combination (FC) preferences. Methods A multiple-choice survey was sent to randomly chosen ophthalmologists throughout the European Union and bordering countries by electronic mail delivery. Ophthalmologists were resent the survey on two more occasions if no response was obtained. Results In total, 50 surveys were received from 530 distributed (9.4% response) from 16 countries. More ophthalmologists prescribed an FC as second (80%) or third choice (64%) therapy than first choice (30%, p=0.0036). As first (p<0.0001) and third choice (p=0.011), the dorzolamide/timolol FC was most commonly prescribed, while as second choice the latanoprost/timolol FC (p<0.0001) was most popular. Overall, 98% (49/50) of doctors believed FC therapy improved patient care most often by better compliance (n=49) and quality of life (n=48, p<0.0001). Most ophthalmologists believed that there was a difference in efficacy between the FC products (32/50, 64%) with the most effective being the bimatoprost/timolol FC (n=12, 24%, p=0.029). However, fewer ophthalmologists perceived safety differences between the products (34/50, 68%). For prostaglandins, dosing time was suggested in the morning by 18 (36%) ophthalmologists and in the evening by 24 (48%) (p=0.35). Conclusions FCs in the European Union are a potentially popular method to reduce intraocular pressure, being prescribed most commonly as second or third choice therapy. The perceived advantages to FC therapy are greater compliance to the medicine and improved patient quality of life.

Sign in / Sign up

Export Citation Format

Share Document